

Imugene Limited to Present at Australia Biotech Invest 2017

MELBOURNE Australia 24 October 2017: Imugene Limited (ASX: IMU) is pleased to announce that Dr Nick Ede, Chief Technology Officer, will present today at the Australia Biotech Invest Conference.

The presentation is attached and will also be available at the Imugene website - <http://www.imugene.com/investor-center/investor-presentations>. Dr Ede will highlight the following;

- Imugene has commenced clinical testing a therapeutic anti-cancer vaccine called HER-Vaxx (IMU-131), in HER2+ gastric cancer patients. HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease. HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US\$8.2 billion.
- A study recently conducted in the US demonstrated that HER-Vaxx (IMU-131) derived antibodies alone, and in combination with Herceptin® at a constant dose, are active against the human HER2+ gastric cancer cell line, NCI-N87. The study demonstrated that anti-HER2 antibodies produced by HER-Vaxx (IMU-131) possess anti-tumour growth inhibitory properties higher than by Herceptin® alone. When the HER-Vaxx antibodies were combined with Herceptin® the inhibition of growth is significantly higher than by Herceptin® alone.

For further information please contact:

Leslie Chong

Chief Executive Officer

E: Leslie.Chong@Imugene.com

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

Imugene is also building a pipeline of small molecule immuno-oncology drugs which modulate the bioavailability of arginine in the tumour microenvironment. Arginine is a critical amino acid for the health of cancer fighting T-cells and depletion of it limits the effectiveness of T-cells to fight tumours.

HER-VAXX IMMUNOTHERAPY FOR HER2+GASTRIC CANCER – CLINICAL AND PIPELINE UPDATE

Dr Nick Ede | Chief Technology Officer
Ausbioinvest, October 24, 2017

1

Notice: Forward looking statements

**Imugene Limited
(ASX:IMU)**

**Level 3, 62 Lygon Street,
Carlton VIC 3053**

**Dr Nick Ede
Chief Technology Officer**


**m: +61 (0) 400 642 254
e: nede@imugene.com
w: imugene.com**

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Imugene Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this brochure include known and unknown risks. As actual results may differ materially to any assumptions made in this brochure, you are urged to view any forward looking statements contained in this brochure with caution. This presentation should not be relied on as a recommendation or forecast by Imugene Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2

EXECUTIVE SUMMARY

- HER-Vaxx Phase 1b/2 clinical study in Her2+ gastric cancer (large unmet medical need by current existing therapies) – **IP protected to 2036**
 - POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenicity established
 - Phase 1b clinical trial underway with **patients successfully dosed**
- **Experienced** management & board
- **Discovery Pipeline:** Mimotope candidate selection to new immuno-oncology targets in development
- **Numerous milestone announcements** & valuation inflection points over next 12-18 months



3

WHAT DOES IMUGENE DO?

Imugene's technology
can induce a patient's body
to make its own specific cancer
eliminating antibodies.

4

A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER?


IN A FACILITY



For example, Roche's Herceptin®

VS

USING B CELLS IN YOUR OWN BODY



Teaching B cells to make antibodies using peptide mimotopes

B Cells are cells in the human body that naturally produce millions of antibodies

5

THE MONOCLONAL ANTIBODY (mAb) MARKET

- Multiple antibody therapies are approved to treat cancer, for example:

Sales in 2016

- Herceptin®: >US\$6.7 billion
- Perjeta®: >US\$1.8 billion
- Rituxan®: >US\$7.3 billion
- YERVOY®: >US\$1.0 billion
- OPDIVO®: >US\$3.7 billion
- KEYTRUDA®: >US\$1.4 billion




Total monoclonal antibody market is currently at US\$60 billion

- All of these antibodies are manufactured in a facility.
- Instead of infusing patients with synthesized antibodies, what if we can induce the patient's own B-cells to make similar cancer-fighting antibodies using Imugene's mimotope technology?


6

HER-Vaxx MIMOTOPE: MECHANISM OF ACTION



HER-Vaxx Demonstrates Superior Activity vs Herceptin®

HER-Vaxx antibodies demonstrate anti-tumour effect by inhibiting validated HER-2+ gastric cell line



*Collaboration with US company 2017

- Research shows superior inhibition of tumour cell growth by HER-Vaxx when compared with Herceptin® in industry validated gastric cancer tumour model
 - Combination of HER-Vaxx sera plus Herceptin is synergistic
 - Opens new clinical and target product profile opportunities (see pipeline slide)
- 8

TEAM WITH A TRACK RECORD IN DRUG DEVELOPMENT



Leslie Chong (Sydney, Australia)

Chief Executive Officer

- Over 19 years of oncology experience in Phase I - III of clinical program development
- Leadership role involvement in 2 marketed oncology products
- Previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco



Prof Ursula Wiedermann (Vienna, Austria)

Chief Scientific Officer

- Co-inventor of HER-Vaxx;
- Professor of Vaccinology at Medical University of Vienna



Dr Axel Hoos (Philadelphia, U.S.A.)

Non-Executive Director


- Currently Senior VP Oncology R&D at GlaxoSmithKline
- Previously Clinical Lead on Ipilimumab at Bristol-Myers Squibb
- Co-Director of the think-tank Cancer Immunotherapy Consortium



Prof Christoph Zielinski (Vienna, Austria)

Head of Scientific Advisory Board

- Chairman of the Comprehensive Cancer Centre in Vienna
- Chairman of the Centre for Eastern EU Organisation for Research and the Treatment of Cancer (CEEORTC)
- Editor in Chief and President Nominee of European Society of Medical Oncology (ESMO)



Paul Hopper (Sydney, Australia)

Executive Chairman


- International & ASX biotech capital markets experience particularly in immuno-oncology & vaccines
- Chairman of Viralytics, Founder & Director of Prescient, Founder of Polynoma LLC, former Director pSivida, Somnomed & Fibrocell Science



Dr Anthony Good (Sydney, Australia)

Clinical Program Manager

- Over 15 years oncology & immunology experience. Active in the development of Viagra, Revatio, Lipitor, Selzentry and Somavert.
- Ex Pfizer Global Research and Development



**HER-Vaxx IS A PHASE 1B/2 STAGE MIMOTOPE
IMMUNOTHERAPY BEING DEVELOPED FOR
HER2+ GASTRIC CANCER**


PHASE 1B/2, IN GASTRIC CANCER COMMENCED

Phase 1b lead-in (FPI – 08/17)

- Open label
- ~Up to 18 patients in 3 cohorts of up to 6 pts per cohort
- Combination with chemo/cisplatin
- Endpoints:
 - Recommended Phase 2 Dose of HER-Vaxx
 - Safety: any HER-Vaxx toxicity
 - Immunogenicity (anti-HER-2 antibody titres)

Phase 2

- Open label
- 68 patients from sites in Asia
- Combination with chemo
- Randomized
- Primary Endpoints:
 - TBD PFS and/or OS
 - (cont. on Ph1b results)
- Secondary endpoint:
 - Immune response



2H, 2017 :
Patients Enrolled

2H, 2017: Early Patient
Data Available

2H, 2017: Interim Ph1b
Patient Data Available

1H, 2018: Final Ph1b
Patient Data Available

We are here – patients
dosed

11

IMUGENE PIPELINE

HER-Vaxx (IMU-131)		Discovery	Pre-Clinical	Phase IB	Phase 2
Open Label Randomized, Controlled Study in Gastric Cancer	Chemotherapy + or - HER-Vaxx				
*Combination Study in breast cancer	HER-Vaxx + Herceptin				▲
*Herceptin Resistant/Failed Study	HER-Vaxx + Chemotherapy		→	▲	
*HER2+ in bladder and ovarian, NSCLC etc.	HER-Vaxx + Chemotherapy		→	▲	

*(IST) Investigator Sponsored or Collaboration study

*Christoph Zielinski, CECOG President, ESMO president nominee, engaged

** Recommended Phase 2 dose

▲ = Initiated upon RP2D**

12

KEY MESSAGES FOR INVESTING

Phase Ib clinical trial
underway with
patients **successfully**
dosed

Discovery Pipeline:
Mimotope candidate
selection to **new**
immuno-oncology
targets

Numerous
milestone
announcements
over next 12
months